Deferasirox in Indian children with thalassemia major: 3 years experience

Indian Journal of Medical and Paediatric Oncology

Volumn 34, Issue 1, 2013, Pages 16-20

  Dhamija, Mayank ^a   Mahajan, Amita ^b   Kalra, Manas ^c   Virmani, Anju ^b  

^a RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

^b INDRAPRASTHA APOLLO HOSPITAL   (India)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Deferasirox; serum ferritin; thalassemia major

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOSIDEROSIS; HUMAN; INDIAN; IRON BALANCE; IRON OVERLOAD; MALE; MICROALBUMINURIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SPLENECTOMY; THALASSEMIA MAJOR; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84879765902     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.113407     Document Type: Article

References (14)

1. Borgne-Pignatto C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Hematologica 2004; 89:1187-93. (Pubitemid 39390442)
2. Olivieri N F, Brittenham G M, McLaren CE, Templeton D M, Cameron RG, McClelland RA, et al. Long term safety and effectiveness of iron chelation therapy with deferiperone for thalassemia major. N Engl J Med 1998;339:417-23. (Pubitemid 28377682)
3. Hoffbrand A, Cohen A, Hershko C. Role of deferiperone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24. (Pubitemid 36759630)
4. Hershko C, Konijn A M, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670-A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radio iron probes of hepatocellular and reticuloendothelial iron stores and in iron- loaded rat heart cells in culture. Blood 2001;97:1115-22. (Pubitemid 32154301)
5. Nisbet Brown E, Olivieri N F, Giardinia PJ, Grady R W, Neufeld E J, Séchaud R, et al. Effectiveness and safety of ICL670 in iron loaded patients with thalassemia: A randomized, double blind, placebo-controlled dose excalation trial. Lancet 2003;361:1597-602.
6. Piga A, Galanello R, Cappellini MO. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003;102:121A.
7. Piga A, Galanello R, Foschini ML. Once-daily treatment with the oral iron chelator ICL670 (Exjade): Results of a phase II study in pediatric patients with beta-thalassemia major. Blood 2004;104:983a. Abstract 3614.
8. Daar S, Taher A, Pathare A. Plasma LPI in beta-thalassemia patients before and after treatment with deferasirox (Exjade (R), ICL670) [abstract]. Blood. 2005;106: 758a. Abstract 2697.
9. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassaemia. Blood 2005;107:3455-62.
10. Cohen AR, Glinn E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in thalassemia major. Blood 2008;111:583-7.
11. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with ?-thalassemia: T he ESCALATOR study. Eur J Haematol 2009;82:458-65.
12. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion dependant anemia and iron overload. Br J Haematol 2009;147:752-9.
13. Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann A K, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009;114:4009-13.
14. Greenberg P, Dine G, Ganser A. Deferasirox (Exjade, ICL 760) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion dependent anemia. Blood, 2005; 106:757a. Abstract 2694.